<DOC>
	<DOCNO>NCT00735397</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability perampanel ( 12 mg/day ) give adjunctive treatment subject refractory partial seizure evaluate maintenance effect perampanel control refractory partial seizure .</brief_summary>
	<brief_title>Evaluation Efficacy Safety E2007 ( Perampanel ) Given Adjunctive Therapy Subjects With Refractory Partial Seizures</brief_title>
	<detailed_description>This open-label extension ( OLE ) study subject complete one follow double-blind , placebo-controlled , Phase 3 study : E2007-G000-304 ( NCT00699972 ) , E2007-G000-305 ( NCT00699582 ) , E2007-G000-306 ( NCT00700310 ) . This OLE study consist 2 phase : Open-label Treatment Phase ( comprise 16-week blinded Conversion Period 256-week Maintenance Period ) Follow-up Phase ( 4 week ) . During Conversion Period , subject investigator remain blinded treatment receive previous DB study . To achieve , subject continue take 6 tablet study medication ( 2 mg perampanel match placebo ) few instruct core Double-Blind ( DB ) study . During open-label Maintenance Period , subject treat perampanel dose provide best combination individual efficacy tolerability .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>Each participant meet follow criterion enrol study : 1. Who complete Visit 8 study E2007G000304 , E2007G000305 , E2007G000306 comply inclusion exclusion criterion study ( exclude criterion related seizure occurrence ) . 2 . Provided write informed consent sign participant legal guardian prior enter study undergo study procedure ( If write informed consent provide legal guardian participant unable , write verbal assent participant obtain ) . 3. Who consider reliable willing available study period record seizures report adverse event self caregiver record report event . 4 . Females either nonchildbearing potential ( define undergone surgical sterilization , postmenopausal [ &gt; age 50 amenorrheic 12 month ] ) childbearing potential . Females childbearing potential enrol agreed abstinent continue use least 1 medically acceptable method contraception ( eg , doublebarrier method [ eg , condom + spermicide , condom + diaphragm spermicide ] , IUD , vasectomise partner ) throughout study period 2 month last dose study drug . Women use hormonal contraceptive require use additional approve method contraception ( describe previously ) continuously throughout entire study period 2 month last dose study drug . ( It require male subject use contraceptive measure base preclinical toxicology data ) . 5 . Continued treated stable dose 1 maximum 3 approve antiepileptic drug . Participants meet follow criterion exclude study : 1 . Those , reason , discontinue early preceding doubleblind study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Partial onset seizure</keyword>
</DOC>